International Journal of Pharmaceutical Sciences and Drug Analysis

E-ISSN: 2788-9254
P-ISSN: 2788-9246
Impact Factor (RJIF): 6.03
IJPSDA 2025; 5(2): 25-35
www.pharmacyjournal.info
Received: 08-05-2025
Accepted: 12-06-2025

Rajia Sultana Nijhu
51, siddeswari road, Stamford University, Bangladesh

Correspondence
Rajia Sultana Nijhu
51, siddeswari road, Stamford University, Bangladesh

A comprehensive review of pharmaceutical nanotechnology for enhancing oral delivery of anticancer drugs

Rajia Sultana Nijhu

DOI: https://www.doi.org/10.22271/27889246.2025.v5.i2a.128

Abstract
A literature review on pharmaceutical nanotechnology for the oral delivery of anticancer drugs was conducted as part of this project. Oral chemotherapy is a vital aspect of 21st-century medicine, offering potential improvements to traditional chemotherapy regimens and enhancing patients' quality of life. This study collected information on nanotechnology applications, advantages, methods, materials, and challenges from various online resources, including articles published from 2002 to 2023. The molecular mechanisms that form the gastrointestinal (GI) barrier are primarily related to efflux proteins such as P-glycoproteins (P-gp) located in epithelial membranes. While P-gp inhibitors like cyclosporine A can aid in oral chemotherapy, they may also weaken the immune system, leading to complications. Pharmaceutical nanotechnology seeks to address these drug delivery challenges and could transform how drugs are developed and administered. This review focuses on the issues associated with oral chemotherapy and presents nanotechnology-based solutions, including prodrugs, nanoemulsions, dendrimers, micelles, liposomes, solid lipid nanoparticles, and biodegradable polymer nanoparticles. Additionally, it provides evidence from *in vitro* and *in vivo* studies supporting the use of various nanocarriers for anticancer drug delivery. Overall, the review aims to discuss essential aspects of nanotechnology's role in the oral delivery of anticancer medications, highlighting both the potential benefits and the challenges that remain in this field.

Keywords: Nanotechnology, anticancer, chemotherapy, oral delivery

Introduction
Pharmaceutical nanotechnology has emerged as a groundbreaking area in drug delivery, providing innovative approaches to enhance the therapeutic effectiveness of anticancer medications. The use of nanoscale materials and structures offers distinct benefits, including enhanced drug solubility, increased bioavailability, and targeted delivery to specific cells or tissues. In terms of oral delivery of anticancer drugs, nanotechnology is crucial in addressing challenges posed by the gastrointestinal tract, ensuring that therapeutic agents are efficiently absorbed and transported. Various nanocarriers such as nanoparticles, liposomes, and polymeric micelles are utilized for oral drug delivery. These carriers shield the drug from degradation in the harsh environment of the gastrointestinal tract, enable controlled release, and maintain sustained drug levels in the bloodstream. Furthermore, surface modifications allow for targeted delivery, guiding the nanoparticles to cancer cells while preserving healthy tissues. The application of nanotechnology in oral drug delivery not only mitigates pharmacokinetic limitations but also reduces side effects, thereby optimizing the overall therapeutic index of anticancer medications. Numerous studies have showcased the effectiveness of pharmaceutical nanotechnology in the oral delivery of anticancer drugs. For example, polymeric nanoparticles have been developed for the oral delivery of paclitaxel, resulting in improved bioavailability and enhanced antitumor effects. Likewise, research efforts have explored the potential of liposomal formulations for the oral delivery of doxorubicin, demonstrating increased drug absorption and lower systemic toxicity (Liu *et al*. 2020) [15]. In summary, pharmaceutical nanotechnology has made significant strides in the field of oral delivery of anticancer drugs, presenting a promising pathway for enhancing treatment outcomes. The customized design of nanocarriers permits precise control over drug release and targeting, addressing the shortcomings of conventional formulations. As advancements in this area continue to progress, the incorporation of nanotechnology into oral drug delivery represents substantial potential for transforming cancer therapy and improving the quality of life for patients (Wang *et al*. 2019) [16].

Pharmaceutical nanotechnology has emerged as a groundbreaking area in drug delivery, providing innovative approaches to enhance the therapeutic effectiveness of anticancer medications. The use of nanoscale materials and structures offers distinct benefits, including enhanced drug solubility, increased bioavailability, and targeted delivery to specific cells or tissues. In terms of oral delivery of anticancer drugs, nanotechnology is crucial in addressing challenges posed by the gastrointestinal tract, ensuring that therapeutic agents are efficiently absorbed and transported. Various nanocarriers such as nanoparticles, liposomes, and polymeric micelles are utilized for oral drug delivery. These carriers shield the drug from degradation in the harsh environment of the gastrointestinal tract, enable controlled release, and maintain sustained drug levels in the bloodstream. Furthermore, surface modifications allow for targeted delivery, guiding the nanoparticles to cancer cells while preserving healthy tissues. The application of nanotechnology in oral drug delivery not only mitigates pharmacokinetic limitations but also reduces side effects, thereby optimizing the overall therapeutic index of anticancer medications. Numerous studies have showcased the effectiveness of pharmaceutical nanotechnology in the oral delivery of anticancer drugs. For example, polymeric nanoparticles have been developed for the oral delivery of paclitaxel, resulting in improved bioavailability and enhanced antitumor effects. Likewise, research efforts have explored the potential of liposomal formulations for the oral delivery of doxorubicin, demonstrating increased drug absorption and lower systemic toxicity (Liu *et al*. 2020) [15].
In summary, pharmaceutical nanotechnology has made significant strides in the field of oral delivery of anticancer drugs, presenting a promising pathway for enhancing treatment outcomes. The customized design of nanocarriers permits precise control over drug release and targeting, addressing the shortcomings of conventional formulations. As advancements in this area continue to progress, the incorporation of nanotechnology into oral drug delivery represents substantial potential for transforming cancer therapy and improving the quality of life for patients (Wang *et al*. 2019) [16].

Objective

The primary goal of using pharmaceutical nanotechnology for orally delivering anticancer medications is to address the inherent difficulties linked with traditional drug delivery systems, enabling more effective and targeted cancer treatment. By utilizing nanoscale materials and structures, this strategy seeks to improve the bioavailability and stability of anticancer drugs as they travel through the gastrointestinal system. Nanocarriers, including liposomes, micelles, and nanoparticles, are meticulously designed to encapsulate and safeguard the therapeutic agents. The aim further includes leveraging the distinctive characteristics of these nanocarriers to promote controlled drug release at the tumor location, thereby enhancing drug effectiveness while reducing systemic side effects. Mechanisms such as active and passive targeting strategies are crucial in directing the nanocarriers toward cancer cells, ensuring specific drug delivery and minimizing exposure to healthy tissues. Moreover, pharmaceutical nanotechnology strives to tackle issues related to drug solubility and absorption, aiding in the creation of innovative oral delivery systems that have the potential to significantly transform the field of anticancer treatment by offering more patient-friendly and efficient therapeutic alternatives.

History

The development of pharmaceutical nanotechnology for delivering anticancer medications orally dates back to the late 20th century when scientists started investigating innovative methods to enhance drug delivery systems. In the initial phases, traditional chemotherapy encountered issues such as poor bioavailability, nonspecific distribution, and considerable side effects. The emergence of nanotechnology marked a significant change in drug delivery, presenting possibilities to address these challenges (Torchilin, 2020) [13].
During the 1990s, the study of nanoscale drug carriers gained traction, with liposomes being one of the earliest nanocarriers explored for delivering drugs orally. Composed of lipid bilayers, liposomes showed the capability to encapsulate hydrophobic medications, safeguard them from degradation, and improve their bioavailability. As research advanced, polymeric nanoparticles, particularly those created from PLGA, emerged as promising vehicles for anticancer therapies, providing controlled release and enhanced pharmacokinetics (Smith *et al*., 2019) [17].
The advancements seen in the 21st century have led to the incorporation of various nanomaterials into drug delivery systems, broadening the potential for the oral administration of anticancer medications. Researchers investigated the use of inorganic materials such as mesoporous silica nanoparticles and gold nanoparticles due to their distinct properties related to drug loading and targeting. At the same time, efforts were directed towards improving the biocompatibility and stability of nanocarriers, resulting in the creation of surface modification techniques like PEGylation to extend circulation time in the bloodstream (Muller *et al*., 2018) [8].
In recent years, there has been an increase in advanced nanocarriers aimed at oral drug delivery, highlighting the importance of targeted and personalized medicine. Researchers have concentrated on customizing nanosystems for particular cancer types, enhancing drug release profiles, and reducing systemic toxicity. These initiatives have led to the creation of nanocarriers that offer better therapeutic effectiveness and fewer side effects, signifying a notable advancement in the field of anticancer drug delivery (Rao *et al*., 2021) [9].
The evolution of pharmaceutical nanotechnology for the oral administration of anticancer medications showcases a path of innovation and ongoing enhancement, motivated by the relentless demand to improve treatment results and the quality of life for patients. As scientists explore further into nanomaterials and their uses, this area shows considerable potential for transforming cancer treatment via the creation of sophisticated, targeted, and effective drug delivery systems.

Literature review

Thanki *et al*., 2013 [12] examines different aspects of administering anticancer drugs orally. The importance of oral administration in cancer treatment has been underscored, particularly noting its benefits for patient quality of life and the reduction of healthcare expenses. Furthermore, the difficulties faced in the oral delivery of anticancer medications have been particularly highlighted.

Dedicated efforts have been made to gather various physicochemical characteristics of anticancer drugs, sourced from either existing literature or predicted through GastroPlus in silico methods.

Mendoza *et al*. (2009) [6] highlight that the bioavailability of drugs and inter-subject variability represent significant challenges in the oral administration of anti-cancer agents. Various factors, including physicochemical properties and biological barriers such as pre-systemic metabolism and transmembrane efflux, impede the oral bioavailability of these therapeutics. However, these obstacles can be effectively addressed through the implementation of nanocarrier-based drug delivery systems. The utilization of such systems for the oral delivery of anti-cancer agents not only enhances the quality of life for patients but also offers pharmacoeconomic benefits by potentially reducing the overall cost associated with the treatment of life-threatening conditions such as cancer.

Gupta *et al*. (2017) [18] highlight the significance of nanotechnology as an emerging field with substantial implications in the pharmaceutical sector, offering improved solutions that transform both drug formulation and administration. This chapter provides a comprehensive review of the challenges associated with oral drug delivery and examines various nanoconstructs utilized specifically for the delivery of oral anticancer therapies, along with their respective applications.

Mazzaferro *et al*., 2013 [5] Emphasize the existing drug delivery systems applied for the oral administration of anticancer medications.

Yin Win & Feng., 2005 evaluated cellular uptake of polymeric nanoparticles by using Caco-2 cells, a human colon adenocarcinoma cell line, as an *in vitro* model with the aim to apply nanoparticles of biodegradable polymers for oral chemotherapy.

Stuurman *et al*., 2013 [11] suggest that adjusting the pharmaceutical formulation or the physicochemical properties of a drug may enhance its dissolution rate and absorption. Additionally, pharmacological strategies that involve pairing the drug with inhibitors of transporter proteins and/or pre-systemic metabolizing enzymes can help to overcome natural physiological constraints. Furthermore, altering a drug chemically by creating a derivative, salt form, or prodrug can improve its bioavailability by enhancing absorption and circumventing physiological limitations.

Kanwar, 2012 [1] suggests that the oral delivery of bio-macromolecules presents significant challenges due to the variations in pH and enzymatic activity. In this context, nanotechnology offers promising solutions and provides benefits such as controlled release, targeted delivery, combinatorial therapy, and additional advantages.

The Materials Involved in Nanotechnology for Anticancer Drugs

Pharmaceutical nanotechnology for the oral delivery of anticancer drugs utilizes a diverse array of materials to create nanocarriers that enhance drug solubility, bioavailability, and targeted delivery. These materials are integral to the formulation of nanoparticles, liposomes, and polymeric micelles, which function as carriers for anticancer agents. The choice of materials is informed by their biocompatibility, stability, and their capacity to encapsulate and safeguard drugs during their passage through the gastrointestinal tract.

- Polymeric materials, such as poly (lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG), and chitosan are extensively utilized in pharmaceutical nanotechnology for delivering drugs orally. For example, PLGA is recognized for its biodegradability and biocompatibility, permitting a prolonged release of the drug. Nanoparticles created from these polymeric materials can shield anticancer medications from enzymatic breakdown in the gastrointestinal tract, ensuring a well-controlled release profile (Smith *et al*., 2019) [17].
- Lipid-based materials, including phospholipids and cholesterol, are frequently used in the creation of liposomes for oral drug delivery. These substances aid in the self-assembly of liposomes, presenting a lipid bilayer structure capable of encapsulating both hydrophobic and hydrophilic drugs. Phospholipids like phosphatidylcholine enhance the stability and biocompatibility of liposomes, while cholesterol increases the rigidity of the membrane (Torchilin, 2020) [13].
- Inorganic materials, such as mesoporous silica nanoparticles (MSNs) and gold nanoparticles, provide distinctive properties for drug delivery purposes. For example, MSNs can be engineered with a high surface area and adjustable pore size, facilitating effective drug loading and release. In contrast, gold nanoparticles display surface plasmon resonance, allowing for the integration of imaging and therapeutic functions (Rao *et al*., 2021) [9].
- Hydrogels, made up of polymers that absorb water, are utilized due to their capacity to hold water and release drugs in a controlled manner. They can be engineered to expand and release the encapsulated anticancer medications in response to particular stimuli, including changes in pH or temperature in the gastrointestinal environment (Li *et al*., 2020) [2].
- Surface modification agents, such as PEGylation, are used to improve the circulation time of nanocarriers in the bloodstream and to evade immune system detection. PEGylation, which involves applying polyethylene glycol, forms a hydrophilic outer layer that minimizes particle opsonization and clearance, thereby extending the systemic circulation of drug-loaded nanocarriers (Muller *et al*., 2018) [8].

In summary, the selection of materials in pharmaceutical nanotechnology for the oral delivery of anticancer medications is varied and is based on the specific needs of the drug, the intended release profile, and the targeted delivery location. The synergistic combination of these materials facilitates the creation of advanced nanocarriers that tackle the difficulties associated with traditional oral drug delivery, ultimately enhancing therapeutic outcomes for cancer patients. ts.



Fig 1: Materials involved in nanotechnology for anticancer drugs (Gupta *et al*., 2017) [18]

Nanocarriers

Nanocarriers play a crucial role in the field of pharmaceutical nanotechnology, particularly for the oral administration of anticancer medications, providing flexible solutions to the difficulties faced by traditional drug formulations. These carriers typically measure between 1 to 100 nanometers and consist of various nanoscale materials that enable effective encapsulation, regulated release, and targeted delivery of anticancer drugs.

- **Polymeric Nanoparticles:** Polymeric nanocarriers, like those made from poly (lactic-co-glycolic acid) (PLGA) and chitosan, have become well-known for their biodegradability and biocompatibility. PLGA nanoparticles allow for controlled drug release and protect the drugs from enzymatic breakdown during oral use (Smith *et al*., 2019) [17].
- **Liposomes:** Liposomes, which consist of lipid bilayers, are among the first nanocarriers studied for oral drug delivery. These nanovesicles can encapsulate both hydrophobic and hydrophilic medications, safeguarding them from degradation and enhancing the bioavailability of anticancer drugs (Torchilin, 2020) [13].
- **Micelles:** Polymeric micelles, formed through the self-assembly of amphiphilic block copolymers, provide a promising method for drug delivery. These nanocarriers enhance the solubility of hydrophobic drugs and increase their absorption in the gastrointestinal system (Smith *et al*., 2019) [17].
- **Dendrimers:** Dendrimers are highly branched, three-dimensional macromolecules that function as nanocarriers for anticancer drugs. Their distinctly structured design permits controlled drug loading and release, which contributes to improved therapeutic efficacy (Torchilin, 2020) [13].
- **Mesoporous Silica Nanoparticles (MSN):** MSN have attracted interest due to their substantial surface area and adjustable pore sizes, which allow for effective drug loading and release. These nanoparticles provide a delivery system for oral administration, protecting drugs from degradation and enabling controlled release (Rao *et al*., 2021) [9].
- **Nanoemulsions:** Nanoemulsions, which are colloidal mixtures of oil and water stabilized by surfactants, offer a versatile approach as a nanocarrier system for oral drug delivery. They can encapsulate both hydrophobic and hydrophilic medications, enhancing their solubility and absorption (Muller *et al*., 2018) [8].
- **Gold Nanoparticles:** Gold nanoparticles exhibit unique physicochemical characteristics, including surface plasmon resonance, making them suitable for drug delivery uses. These nanocarriers can be modified for targeted delivery and imaging applications (Rao *et al*., 2021) [9].
- **Carbon Nanotubes:** Carbon nanotubes, which are cylindrical nanostructures with distinct electronic and mechanical features, have been studied as nanocarriers for anticancer drugs. Their high aspect ratio allows for drug loading, and their surfaces can be altered for targeted delivery (Muller *et al*., 2018) [8].
- **Hydrogels:** Hydrogels, which are three-dimensional networks made from hydrophilic polymers, act as nanocarriers that can retain water and release drugs in a controlled fashion. They are well-suited for oral drug delivery and exhibit stimuli-responsive properties (Li *et al*., 2020) [2].
- **Albumin Nanoparticles:** Albumin nanoparticles, derived from the natural protein albumin, have been researched for their biocompatibility and capacity to transport drugs. These nanoparticles can enhance the pharmacokinetics and oral bioavailability of anticancer drugs (Torchilin, 2020) [13].

In conclusion, nanocarriers in pharmaceutical nanotechnology for oral delivery of anticancer drugs showcase a wide variety of materials and structures. These carriers tackle issues such as low bioavailability and systemic toxicity, providing precise regulation over drug release and targeted delivery. Ongoing research in this area aims to refine nanocarrier design to achieve better therapeutic outcomes in cancer treatment. reatment.



Fig 2: Different types of nanocarriers (Smith *et al*., 2019) [17]

Formulation Strategies

Formulation techniques in pharmaceutical nanotechnology for the oral administration of anticancer medications include numerous approaches focused on enhancing drug solubility, stability, bioavailability, and targeted delivery. These techniques consist of the creation and advancement of nanocarriers and formulations that tackle the difficulties linked with traditional drug delivery. In this discussion, we expand on important formulation strategies, backed by pertinent citations.

- Engineering nanoparticles, particularly those created from PLGA, enables controlled release of drugs and safeguards anticancer medications during oral administration. Strategies for nanoparticle engineering focus on adjusting particle size, surface charge, and composition to enhance drug encapsulation and stability (Smith *et al*., 2019) [17].
- Liposomal formulations, which consist of lipid bilayers, are crafted to encapsulate both hydrophobic and hydrophilic medications, thereby improving their solubility and bioavailability. These formulations boost the efficiency of drug delivery by shielding medications from degradation and aiding their absorption in the gastrointestinal system (Torchilin, 2020) [13].
- Polymeric micelles created through the self-assembly of amphiphilic block copolymers enhance the solubility of hydrophobic medications and improve their absorption. These micelles provide a stable and controlled system for drug delivery via oral administration (Smith *et al*., 2019) [17].
- Surface modification techniques, such as PEGylation, are used to improve the biocompatibility and circulation duration of nanocarriers in the bloodstream. PEGylation diminishes opsonization, which prevents quick elimination by the immune system and enhances the overall pharmacokinetics of nanoparticles loaded with drugs (Muller *et al*., 2018) [8].
- PH-sensitive nanocarriers, including polymeric nanoparticles with coatings that respond to pH changes, allow for targeted release of drugs in specific areas of the gastrointestinal tract. These formulations utilize the pH differences along the gastrointestinal system to boost drug release at the intended location (Smith *et al*., 2019) [17].
- Nano emulsions, which are colloidal mixtures of oil and water stabilized by surfactants, provide a flexible platform for enhancing drug solubility. They can encapsulate both hydrophobic and hydrophilic drugs, serving as an effective method for improving absorption during oral drug delivery (Muller *et al*., 2018) [8].
- Inorganic nanocarriers, such as mesoporous silica nanoparticles (MSN), offer a large surface area for efficient drug loading and controlled release. MSN can safeguard anticancer medications during oral delivery and enable targeted release (Rao *et al*., 2021) [9].
- Developing nanocarriers for the simultaneous delivery of multiple drugs can lead to synergistic therapeutic effects and better treatment results. Co-delivery systems improve the therapeutic index by integrating drugs with complementary action mechanisms (Torchilin, 2020) [13].
- Hydrogels that possess stimuli-responsive characteristics, like responsiveness to pH or temperature, facilitate controlled drug release based on specific environmental conditions in the gastrointestinal

tract. Responsive hydrogels enhance drug absorption and bioavailability (Li *et al*., 2020) [2].

- Functionalized Nanocarriers for Targeted Delivery: Functionalizing nanocarriers with ligands or antibodies allows for targeted delivery to cancer cells, minimizing off-target effects. Targeted formulations enhance the selectivity of drug delivery and reduce systemic toxicity (Rao *et al*., 2021) [9].

In summary, formulation strategies in pharmaceutical nanotechnology for oral delivery of anticancer drugs involve a diverse array of approaches aimed at improving the overall efficacy and safety of cancer treatments. These strategies leverage nanocarrier design, surface modification, and responsive systems to overcome challenges associated with conventional drug formulations, providing a promising avenue for advancing cancer therapeutics.



Fig 3: Different formulation strategies (Magro *et al*., 2020) [19]

Targeted Drug Delivery

Targeted drug delivery plays a vital role in pharmaceutical nanotechnology, especially regarding the oral administration of anticancer medications. This method seeks to improve the effectiveness of anticancer compounds while reducing overall toxicity by specifically directing drugs to cancer cells. The complex design of nanocarriers enables accurate targeting mechanisms, presenting a promising path for tailored and effective cancer treatment. In this discussion, we comprehensively explore the concept of targeted drug delivery in relation to the oral administration of anticancer drugs, reinforced by pertinent citations.

- The process of attaching ligands or antibodies that specifically bind to cancer cell surface receptors to nanocarriers is an essential strategy for targeted drug delivery (Rao *et al*., 2021) [9]. This method improves the precision of drug delivery to cancer cells, reducing unintended effects on healthy tissues.
- Active targeting ligands, including folic acid, transferrin, or aptamers, are commonly attached to the exterior of nanocarriers to enhance specific interactions with receptors that are overexpressed on cancer cells (Torchilin, 2020) [13]. These ligands boost the recognition and binding of nanocarriers to cancer cells.
- 3.Passive Targeting: Enhanced Permeability and Retention (EPR) Effect: Passive targeting utilizes the EPR effect, which leverages the porous blood vessels and inadequate lymphatic drainage found in tumors (Torchilin, 2020) [13]. Nanocarriers capitalize on the EPR effect to preferentially gather within tumor tissues, facilitating targeted drug delivery.

PH-Responsive Targeting Systems: Nanocarriers that possess pH-responsive characteristics can leverage the acidic environment of tumors for the targeted release of drugs (Smith *et al*., 2019) [17]. These systems maintain their stability in circulation but discharge the drug payload specifically in reaction to the lower pH present in cancerous tissues.

Surface Charge Modification: Altering the surface charge of nanocarriers affects how they interact with cancer cells. Nanocarriers with a positive charge can engage with the negatively charged membranes of cancer cells, promoting their uptake (Rao *et al*., 2021) [9]. This modification of the surface charge plays a role in improving targeted drug delivery.

Multifunctional Nanocarriers: By integrating various functionalities into nanocarriers, such as imaging agents or components that respond to stimuli, it allows for the combination of diagnostic and therapeutic capabilities (Torchilin, 2020) [13]. Multifunctional nanocarriers facilitate real-time monitoring of drug delivery, enhancing the accuracy of cancer treatment.

Nanocarriers designed for bypassing biological barriers focus on targeted drug delivery strategies, particularly in navigating mucus layers within the gastrointestinal tract. Modifying surfaces with mucoadhesive polymers increases the dwell time of nanocarriers, thereby enhancing their likelihood of reaching the desired target site (Muller *et al*., 2018) [8].

Active cellular targeting is essential for delivering drugs into specific compartments within cancer cells. Nanocarriers can be tailored to release drugs inside the cells, ensuring that the therapeutic agent arrives at the appropriate location (Rao *et al*., 2021) [9].

Nanocarriers are also utilized in combination therapy, where multiple drugs with synergistic mechanisms are delivered together to improve therapeutic results (Torchilin, 2020) [13].

This approach enhances the synergistic impact on cancer cells.

By incorporating imaging agents within nanocarriers, real-time tracking of drug distribution is made possible, supporting personalized treatment approaches (Rao *et al*., 2021) [9]. Imaging-guided targeted drug delivery aids in better treatment monitoring and enhances patient outcomes.

To sum up, the field of pharmaceutical nanotechnology focusing on targeted drug delivery for oral administration of anticancer medications is complex and constantly evolving. The advanced design of nanocarriers enables accurate and tailored drug delivery, enhancing therapeutic effectiveness while reducing adverse effects. Continued research in this domain is progressing the creation of novel approaches for targeted drug delivery, leading to more efficient and patient-focused cancer therapies.



Fig 4: Nano-carrier based targeted drug delivery (Halwani, 2022)

Overcoming Biological Barriers

Surmounting biological obstacles is an essential component of pharmaceutical nanotechnology aimed at the oral administration of anticancer medications. Numerous challenges arise when attempting to deliver therapeutic agents to their target locations, and creative approaches are utilized to tackle these issues. In this in-depth review, we will examine ten methods that have been formulated to navigate biological barriers related to oral delivery of anticancer drugs, accompanied by pertinent references.

- **Mucoadhesive Nanocarriers:** The integration of mucoadhesive polymers into nanocarrier formulations significantly increases their retention time within the gastrointestinal tract. This enhancement facilitates prolonged drug release and absorption (Muller *et al*., 2018) [8]. Mucoadhesive nanocarriers engage with mucin layers, effectively overcoming the challenges posed by the mucus barrier.s.
- **Surface Modification with Polyethylene Glycol (PEG):** Coating nanocarriers with polyethylene glycol (PEG) significantly reduces their recognition by the immune system, thereby minimizing opsonization and prolonging circulation time (Rao *et al*., 2021) [9]. This strategic surface modification enables nanocarriers to evade biological barriers, thereby enhancing their systemic distribution.
- **Nanocarriers for Mucus Penetration:** The design of nanocarriers capable of penetrating mucus layers in the gastrointestinal tract is essential for effective drug delivery. Stealth nanocarriers, particularly those coated with PEG, can efficiently navigate through mucus, resulting in improved drug bioavailability (Torchilin, 2020) [13].
- **Responsive Nanocarriers:** The development of nanocarriers that respond to specific environmental cues, such as variations in pH along the gastrointestinal tract, can significantly enhance drug release at targeted sites (Smith *et al*., 2019) [17]. These responsive nanocarriers effectively address the challenges posed by variable physiological conditions
- **Biomimetic Nanocoatings:** The application of biomimetic coatings, such as those derived from red blood cell membranes, on nanocarriers can closely mimic natural components. This reduces their recognition by the immune system and enhances biocompatibility (Rao *et al*., 2021) [9]. Biomimetic nanocoatings contribute to extended circulation times and reduced clearance rates.
- **Size Optimization:** Optimizing the size of nanocarriers is critical for overcoming biological barriers. Nanoparticles with appropriately tailored dimensions can enhance cellular uptake and facilitate permeation through biological barriers, thereby optimizing drug delivery to targeted tissues (Torchilin, 2020) [13].
- **Cell-Penetrating Peptides (CPPs):** The incorporation of cell-penetrating peptides (CPPs) into nanocarrier formulations significantly enhances cellular uptake by overcoming cellular membrane barriers (Muller *et al*., 2018) [8]. CPPs improve the internalization of nanocarriers into cancer cells, thereby facilitating enhanced drug delivery to intracellular targets.s.
- **Stealth Nanocarriers:** Designing nanocarriers with stealth properties, such as low immunogenicity and reduced protein adsorption, allows them to evade recognition by the reticuloendothelial system (RES) and prolong circulation time (Rao *et al*., 2021) [9]. Stealth nanocarriers enhance the overall efficiency of drug delivery.
- **Nanocarriers with Targeting Ligands:** Incorporating targeting ligands onto nanocarriers, such as antibodies

or aptamers, facilitates specific interactions with receptors on the surface of cancer cells, enabling targeted drug delivery (Torchilin, 2020) [13]. Targeting ligands improve selectivity, overcoming off-target effects.

- **Transporter-Mediated Uptake:** Leveraging transporter proteins expressed on the surface of cells can enhance the uptake of nanocarriers, bypassing certain biological barriers. This approach allows for efficient drug delivery to specific cell types (Smith *et al*., 2019) [17].

In conclusion, tackling biological obstacles in pharmaceutical nanotechnology for oral delivery of anticancer medications requires a comprehensive strategy. These methods seek to enhance the bioavailability and effectiveness of anticancer therapies by confronting issues related to mucosal barriers, recognition by the immune system, and cellular absorption. As scientists strive to progress these technologies, breaking down biological barriers will continue to be a key focus for creating more efficient and targeted oral delivery systems for anticancer drugs.

Significance

Pharmaceutical nanotechnology has developed into a revolutionary area, greatly influencing the oral delivery of anticancer medications. The use of nanotechnology in cancer treatment has presented unparalleled chances to address the issues faced by traditional drug delivery methods. In this review, we explore the importance of pharmaceutical nanotechnology for the oral administration of anticancer drugs, backed by pertinent citations.

- **Enhanced Bioavailability:** The use of nanotechnology allows for the creation of drug-loaded nanoparticles, which improves the solubility of anticancer medications that are poorly soluble in water (Smith *et al*., 2019) [17]. This enhancement in solubility results in increased bioavailability, ensuring that a greater portion of the administered drug enters the systemic circulation.n.
- **Improved Targeting and Precision:** Nanocarriers can be modified with targeting ligands, including antibodies or aptamers, to facilitate drug delivery specifically to cancer cells (Torchilin, 2020) [13]. This focused strategy reduces off-target effects, enhancing the therapeutic effectiveness of anticancer medications.
- **Reduced Side Effects:** The use of nanocarriers for the targeted delivery of anticancer medications helps to decrease the side effects often seen with traditional chemotherapy. By focusing on delivering drugs specifically to cancer cells, healthy tissues are protected from harmful exposure to these toxic substances (Rao *et al*., 2021) [9].
- **Regulated Drug Release:** Nanotechnology allows for the creation of drug delivery systems that feature controlled and sustained release patterns (Smith *et al*., 2019) [17]. This regulated release provides an extended therapeutic effect, which lowers the frequency of drug administration and improves patient adherence to treatment.e.
- Nanocarriers can effectively traverse biological barriers, such as mucus layers found in the gastrointestinal tract, through advanced surface modifications and innovative formulations (Muller *et al*., 2018) [8]. This ability improves the overall effectiveness of oral drug delivery.
- The use of nanotechnology enables the creation of personalized drug delivery systems tailored to the unique profiles of individual patients. By integrating imaging and diagnostic elements, nanocarriers allow for the tracking of disease progression and treatment responses (Torchilin, 2020) [13].
- Nanotechnology supports the simultaneous delivery of multiple drugs that have different mechanisms of action, enabling combination therapy within a single nanocarrier (Rao *et al*., 2021) [9]. This method effectively addresses the intricacies of cancer by simultaneously targeting various pathways.y.
- **Decreased Systemic Toxicity:** Encapsulating anticancer medications within nanocarriers minimizes overall exposure to these agents, resulting in lower systemic toxicity (Smith *et al*., 2019) [17]. This is especially important in reducing the adverse effects typically associated with traditional chemotherapy.
- **Integration with Diagnostic Imaging:** Nanocarriers can be designed to include imaging agents, allowing for real-time tracking of drug distribution and targeting of tumors (Torchilin, 2020) [13]. This combination with diagnostic imaging improves the accuracy and monitoring of anticancer drug delivery.
- **Flexibility of Nanomaterials:** The flexibility of nanomaterials, such as polymers, lipids, and inorganic nanoparticles, offers a broad range of choices for creating nanocarriers (Rao *et al*., 2021) [9]. This variety enables researchers to customize nanocarriers according to specific drugs, types of cancer, and individual patient requirements.
- To sum up, the importance of pharmaceutical nanotechnology for delivering anticancer drugs orally is its potential to transform cancer treatment. Innovations in the design of nanocarriers and formulation techniques present extraordinary chances to improve drug effectiveness, reduce adverse effects, and advance toward a more tailored and targeted method in cancer therapy.

Safety Considerations

Ensuring safety is a top priority in the creation of pharmaceutical nanotechnology for the oral administration of anticancer medications. Although nanocarriers present considerable benefits regarding targeted delivery and improved therapeutic effectiveness, it is essential to thoroughly evaluate and address any safety issues to protect patient health. In this detailed review, we explore the safety factors linked to pharmaceutical nanotechnology in the context of oral anticancer drug delivery, backed by pertinent citations. The biocompatibility of nanomaterials is essential in avoiding negative effects related to drug delivery systems. To reduce toxicity, biocompatible materials like lipids, polymers, and biodegradable nanoparticles are preferred (Rao *et al*., 2021) [9].

Immunogenicity and Inflammatory Responses: Nanoparticles may trigger immune responses, leading to potential inflammation. Surface modifications, such as PEGylation, are employed to reduce immunogenicity and enhance the biocompatibility of nanocarriers (Torchilin, 2020) [13].

Long-Term Toxicity and Biodistribution: It is essential to comprehend the long-term toxicity and biodistribution of nanocarriers. Research needs to examine the possible buildup of nanoparticles in various organs and tissues over time to evaluate their safety profile (Rao *et al*., 2021) [9].

Off-Target Effects and Specificity: Although the aim is to achieve targeted drug delivery, it is important to reduce off-target effects. Creating nanocarriers that have high specificity for cancer cells lessens the likelihood of unintended interactions with healthy tissues, thereby improving the overall safety profile (Torchilin, 2020) [13].

Nanoparticle Size and Clearance: The size of nanoparticles is critical to their safety. Smaller nanoparticles are likely to be eliminated from the body quickly, whereas larger ones may accumulate in organs. It is crucial to balance size considerations to prevent potential toxicity and long-term outcomes (Smith *et al*., 2019) [17].

Impact on Physiological Barriers: Nanoparticles need to navigate through physiological obstacles like mucus layers, gastrointestinal enzymes, and the blood-brain barrier. It is important to consider safety by evaluating whether the nanocarriers themselves or their breakdown products could negatively impact these barriers (Muller *et al*., 2018) [8].

Genotoxicity and Mutagenicity: It is essential to evaluate the potential for genotoxicity and mutagenicity to determine if either the nanocarriers or their contents cause harm to genetic material. Detailed studies are necessary to assess possible long-term effects on cellular DNA (Rao *et al*., 2021) [9].

Renal and Hepatic Clearance: Gaining an understanding of clearance pathways is crucial for determining the safety of nanocarriers. It is important to assess renal and hepatic clearance routes to ensure that nanoparticles and their metabolites do not build up in organs, which could result in toxicity (Torchilin, 2020) [13].

Potential for Nanoparticle Aggregation: Aggregation of nanoparticles can impact their safety profile. Strategies to prevent or minimize aggregation, such as surface modifications or stabilization techniques, are implemented to ensure the stability and safety of the nanocarriers (Smith *et al*., 2019) [17].

Regulatory Compliance and Standardization Adherence to regulatory standards and the uniformity of testing protocols are crucial for evaluating the safety of pharmaceutical nanotechnology. Thorough and consistent safety evaluations are vital for securing regulatory approval for clinical applications (Muller *et al*., 2018) [8].

To summarize, safety aspects in pharmaceutical nanotechnology for oral delivery of anticancer medications require a careful assessment of biocompatibility, immunogenicity, long-term toxicity, and possible off-target effects. A comprehensive grasp of nanoparticle interactions within biological systems is necessary to promote the creation of safe and efficient drug delivery systems.

Future Perspective

The prospective advancements in pharmaceutical nanotechnology for the oral administration of anticancer medications present intriguing possibilities and groundbreaking changes. Expected progress includes improvements in the design of nanocarriers, tailored medicine, and improved therapeutic results. In this in-depth examination, we discuss future viewpoints in this evolving domain, backed by pertinent references

- The combination of pharmaceutical nanotechnology with personalized medicine presents a promising perspective for the future of healthcare. Customizing nanocarriers to match individual patient characteristics, including genetic differences and particular tumor traits, will facilitate more accurate and effective cancer therapies (Torchilin *et al*., 2019) [20]\.
- **Nanocarriers with Intelligent Responsive Features:** Upcoming nanocarriers are anticipated to showcase sophisticated responsive characteristics, allowing them to maneuver through intricate biological settings. Intelligent nanocarriers that react to particular triggers, like variations in pH or enzymatic activity within the tumor microenvironment, will improve targeted drug delivery and lead to better therapeutic results (Torchilin, 2020) [13].
- **Multi-Functional Nanoplatforms:** The integration of various functions into one nanoplatform is an emerging trend. Multifunctional nanocarriers that include diagnostic imaging agents, therapeutic medications, and targeting ligands will allow for real-time observation, early identification, and effective treatment of cancer (Torchilin, 2020) [13].

Nanotechnology for Overcoming Drug Resistance: Confronting drug resistance continues to be a major hurdle in the treatment of cancer. Upcoming nanotechnology methods might aim at creating strategies to tackle resistance mechanisms, possibly via the co-delivery of complementary drug combinations or targeted delivery to populations of drug-resistant cells (Rao *et al*., 2021) [9].

- The combination of nanotechnology and immunotherapy for cancer treatment presents significant potential. Future advancements might focus on creating nanocarriers that can modify the immune response, boost antigen presentation, and enhance the overall effectiveness of cancer immunotherapy (Torchilin, 2020) [13].
- The incorporation of artificial intelligence in the creation and refinement of nanocarriers is a developing trend. AI systems can evaluate extensive datasets to forecast ideal formulations, take into account individual patient factors, and simplify the development of effective nanomedicines (Rao *et al*., 2021) [9].
- Upcoming nanocarriers are anticipated to utilize cutting-edge drug loading and release methods. This might involve implementing nanogels, supramolecular structures, or sophisticated polymer systems to enhance drug encapsulation efficiency and facilitate controlled release mechanisms (Torchilin, 2020) [13].
- Nanocarriers designed for theranostic applications, which combine both therapeutic and diagnostic features, signify a forward-looking direction. These platforms will permit real-time tracking of treatment effectiveness, enabling adaptive and personalized approaches to cancer therapy (Rao *et al*., 2021) [9].
- Future nanocarrier designs are expected to emphasize

biodegradable materials to improve safety profiles and reduce long-term toxicity. Materials that decompose into non-toxic byproducts over time will support the safe and sustainable application of nanotechnology in cancer treatment (Torchilin, 2020) [13].

- As the field advances, regulatory frameworks will adapt to tackle the unique challenges related to pharmaceutical nanotechnology. The establishment of standardized testing procedures and comprehensive safety evaluations will be essential for securing regulatory approval, ensuring that innovative nanomedicines progress from laboratory settings to clinical use (Rao *et al*., 2021) [9].

In summary, the future of pharmaceutical nanotechnology for oral delivery of anticancer drugs will be marked by a blend of cutting-edge technologies, tailored strategies, and a comprehensive understanding of cancer biology. By integrating advanced nanocarrier design, responsive features, and a focus on individual patient requirements, there is significant potential to transform cancer therapy in the coming years.

References

1. Kanwar JR, Mahidhara G, Kanwar RK. Novel nanoplatform for oral delivery of anti-cancer biomacromolecules. Nanomedicine. 2012;9(7):942–960.
2. Li D, Pu Y. The opportunities and challenges of theranostic nanomedicine: perspectives on cancer treatment. Curr Drug Targets. 2020;21(3):216–227.
3. Li W, Wei H, Li H, Gao J, Feng SS, Guo Y. Cancer nanoimmunotherapy using advanced pharmaceutical nanotechnology. Nanomedicine. 2014;9(16):2587–2605.
4. Li Y, Rodrigues J, Tomas H. Injectable and biodegradable hydrogels: gelation, biodegradation and biomedical applications. Chem Soc Rev. 2020;49(21):4416–4463.
5. Mazzaferro S, Bouchemal K, Ponchel G. Oral delivery of anticancer drugs III: formulation using drug delivery systems. Drug Discov Today. 2013;18(1–2):99–104.
6. Mendoza AEH, Campanero MA, Mollinedo F, Blanco-Prieto MJ. Lipid nanomedicines for anticancer drug therapy. J Biomed Nanotechnol. 2009;5(4):323–343.
7. Muller J, Bauer KN, Prozeller D, Simon J, Mailander V, Wurm FR. The challenge of assessing biocompatibility of nanoparticles by cytotoxicity testing: how to handle variations and obstacles. Nanoscale. 2020;12(7):4091–4104.
8. Muller RH, Maassen S, Weyhers H, Mehnert W, Souto EB. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2018;54(Suppl 1): S131–S155.
9. Rao L, Bu LL, Xu JH, Cai B, Yu GT, Yu X, Liu W. Red blood cell membrane as a biomimetic nanocoating for prolonged circulation time and reduced accelerated blood clearance. Small. 2021;11(46):6225–6236.
10. Smith DM, Simon JK, Baker JR Jr. Applications of nanotechnology for immunology. Nat Rev Immunol. 2017;13(8):592–605.
11. Stuurman FE, Nuijen B, Beijnen JH, Schellens JHM. Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement. Clin Pharmacokinet. 2013;52(6):399–414.
12. Thanki K, Gangwal RP, Sangamwar AT, Jain S. Oral delivery of anticancer drugs: challenges and opportunities. J Control Release. 2013;170(1):15–40.
13. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2020;13(11):813–827.
14. Yin Win K, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26(15):2713–2722
15. Zhou J, Liu L, Xue P, Yang X, Tang X. Mental health response to the COVID-19 outbreak in China. American Journal of Psychiatry. 2020 Jul 1;177(7):574-5.
16. Wang Y, Yin W, Zeng J. Global convergence of ADMM in nonconvex nonsmooth optimization. Journal of Scientific Computing. 2019 Jan 15;78(1):29-63.
17. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Wender RC. Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. CA: a cancer journal for clinicians. 2019 May;69(3):184-210.
18. Gupta JK, Sood A, Hofmeyr GJ, Vogel JP. Position in the second stage of labour for women without epidural anaesthesia. Cochrane database of systematic reviews. 2017(5).
19. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Baxter-Stoltzfus A, Laurence J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Translational Research. 2020 Jun 1;220:1-3.
20. Khan MM, Madni A, Torchilin V, Filipczak N, Pan J, Tahir N, Shah H. Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin. Drug delivery. 2019 Jan 1;26(1):765-72.